Resources
Learn more about what Greenbrook can offer you and your patient
NeuroStar TMS Therapy
NeuroStar TMS (Transcranial Magnetic Stimulation) therapy is a FDA-cleared, non-medicated treatment for those with Major Depressive Disorder and Obsessive Compulsive Disorder.
TMS at a Glance
How does NeuroStar TMS work?
Learn moreUnlike medications, which affect the entire body as they pass through the blood-brain barrier, NeuroStar TMS therapy targets depression at the source. It works via magnetic pulses that induce electrical currents, stimulating neurons for a therapeutic effect.
Who is a NeuroStar TMS candidate?
Learn moreNeuroStar TMS (Transcranial Magnetic Stimulation) therapy is FDA-cleared for people 15 years of age and older with Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD) who have failed to achieve satisfactory improvement from previous antidepressant medication treatment.
When is NeuroStar TMS indicated?
When is it indicated?Research indicates that 83% of patients experience at least a 50% reduction in depressive symptoms after treatment, with 62% achieving remission and nearly complete relief. In one study, 62.5% of those who saw improvement continued to see positive results or remained in remission a year later.
NeuroStar TMS therapy for OCD
Learn moreNeuroStar TMS is an FDA-cleared treatment option for Obsessive-Compulsive Disorder. The OCD protocol has key technical differences than MDD protocol, including different pattern of stimulation targeting the medial prefrontal cortex.
SPRAVATO® Esketamine at a Glance
How does SPRAVATO® work?
Traditional antidepressants are believed to work by boosting serotonin and other neurotransmitters, which then influence glutamate—a brain chemical that helps regulate mood and depression. SPRAVATO® uses esketamine, and is thought to directly target the glutamate system, activating receptors that promote the formation of new pathways in the brain. Although SPRAVATO® is FDA-approved for treatment-resistant depression and for alleviating depressive symptoms in adults with major depressive disorder who experience suicidal thoughts or actions, researchers are actively studying its full impact.
Who is a Spravato® candidate?
SPRAVATO® esketamine nasal spray is FDA-approved for people with depression who have not experienced adequate improvement with antidepressant medications.
Who shouldn't take SPRAVATO®?
Greenbrook recommends calling for more information on whether treatment is right for your patient. Below are some of the common contraindications, but each patient's journey is unique.
- Uncontrolled hypertension
- History of stroke or brain bleeds
- Abnormal blood vessels at risk of bleeding, such as aneurysms or arteriovenous malformations (AVMs)
- Sensitivity to esketamine or ketamine
SPRAVATO®
SPRAVATO® is an FDA-approved esketamine nasal spray, a refined form of ketamine, used to treat adults with treatment-resistant depression and depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.
What can your patient expect when doing treatment?
Patient Journey
Our Care Team is here for you & your patients
Hear Real Stories from Real Patients
Do you have a patient who would benefit from treatment with us?
Help them get started today.
